Related Experiment Video
Updated: Feb 7, 2026
10:08
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
14.0K
[Metilin Improves Сardiac Function in Rabbits With Chronic Heart Failure]
I M Studneva1, V L Lakomkin1, O M Veselova1
1National Medical Research Center for Cardiology.
Kardiologiia
|August 8, 2018
Summary
Metilin, a cardioprotective drug, improved cardiac function in rabbits experiencing doxorubicin-induced heart failure. This drug shows potential in mitigating chemotherapy-related cardiac damage.
Area of Science:
- Cardiology
- Pharmacology
- Oncology
Background:
- Doxorubicin chemotherapy can cause cardiotoxicity, leading to left ventricular (LV) dysfunction and chronic heart failure (CHF).
- Existing treatments for doxorubicin-induced cardiotoxicity are limited, necessitating the development of novel cardioprotective agents.
Purpose of the Study:
- To evaluate the cardioprotective effects of metilin, a novel drug developed at the National Medical Research Center of Cardiology.
- To assess metilin's impact on cardiac function indices in a rabbit model of doxorubicin-induced cardiotoxicity.
Main Methods:
- Rabbits received weekly intravenous doxorubicin for 8 weeks to induce cardiotoxicity.
- Cardiac function was assessed using echocardiography and LV catheterization.
- Biomarkers of myocardial damage, including malondialdehyde (MDA), troponin (TnI), and creatine kinase-MB (CK-MB), were measured.
Main Results:
- Doxorubicin administration resulted in decreased body mass, elevated cardiac biomarkers, and impaired LV structure and function, evidenced by increased end-diastolic and end-systolic dimensions (EDD, ESD) and reduced shortening fraction (SF) and ejection fraction (EF).
- Intravenous metilin infusion significantly improved SF and EF in doxorubicin-treated rabbits, indicating enhanced cardiac contractility and relaxation.
- The beneficial effects of metilin on cardiac function persisted after infusion cessation and were more pronounced in rabbits with doxorubicin-induced CHF.
Conclusions:
- Metilin demonstrates significant cardioprotective potential against doxorubicin-induced left ventricular dysfunction.
- The drug may serve as a valuable therapeutic agent for mitigating cardiotoxicity in patients undergoing doxorubicin chemotherapy.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
964
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
964
01:17Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:22Heart Failure Drugs: Diuretics
987
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
987
01:30Heart Failure V: Medical Management
330
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330